Inventor · disambiguated record
Frank J. Calzone
Also filed as: CALZONE FRANK J · CALZONE Frank
22 granted patents·9 pending applications·656 citations·filing 1995–2021
96Inventor score
Files withAMGEN INC16REMD BIOTHERAPEUTICS INC7CALZONE FRANK J2AMGEN INC A CORP OF THE STATE1BELTRAN PEDRO J1
Top patents by PatentIndex Score
31 records- 0196US7871611B2Compositions and methods relating to anti IGF-1 receptor antibodiesAMGEN INC·Filed 2005·Granted Jan 18, 2011·46 cites·16 claims
- 0296US6015938AOsteoprotegerinAMGEN INC·Filed 1997·Granted Jan 18, 2000·158 cites·2 claims
- 0395US6284485B1Nucleic acids encoding osteoprotegerinAMGEN INC·Filed 1997·Granted Sep 4, 2001·123 cites·16 claims
- 0492US8168409B2Compositions and methods relating to anti-IGF-1 receptor antibodiesCALZONE FRANK J·Filed 2010·Granted May 1, 2012·13 cites·33 claims
- 0591US6288032B1OsteoprotegerinAMGEN INC·Filed 1997·Granted Sep 11, 2001·56 cites·14 claims
- 0690US6284728B1OsteoprotegerinAMGEN INC·Filed 1997·Granted Sep 4, 2001·57 cites·9 claims
- 0790US6284740B1OsteoprotegerinAMGEN INC·Filed 1997·Granted Sep 4, 2001·56 cites·20 claims
- 0887US6767541B2HER-2/neu overexpression abrogates growth inhibitory pathwaysUNIV CALIFORNIA·Filed 2001·Granted Jul 27, 2004·37 cites·19 claims
- 0986US6369027B1OsteoprotegerinAMGEN INC·Filed 1996·Granted Apr 9, 2002·65 cites·19 claims
- 1085US11319372B2Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)REMD BIOTHERAPEUTICS INC·Filed 2018·Granted May 3, 2022·3 cites·18 claims
- 1185US7005413B1Combination therapy for conditions leading to bone lossAMGEN INC·Filed 2000·Granted Feb 28, 2006·16 cites·15 claims
- 1284US8460662B2Compositions and methods relating to anti-IGF-1 receptor antibodiesCALZONE FRANK J·Filed 2012·Granted Jun 11, 2013·4 cites·21 claims
- 1379US6613544B1OsteoprotegerinAMGEN INC·Filed 1995·Granted Sep 2, 2003·20 cites·13 claims
- 1476US8895008B2Compositions and methods relating to anti-IGF-1 receptor antibodiesAMGEN INC·Filed 2013·Granted Nov 25, 2014·1 cites·9 claims
- 1572US7632922B1OsteoprotegerinAMGEN INC·Filed 2000·Granted Dec 15, 2009·1 cites·11 claims
- 1669US10035861B2Compositions and methods relating to anti-IGF-1 receptor antibodiesAMGEN INC·Filed 2014·Granted Jul 31, 2018·0 cites·7 claims
- 1763US2010298229A1OsteoprotegerinAMGEN INC·Filed 2009·Application pending·0 cites
- 1860US2005221331A1OsteoprotegerinAMGEN INC·Filed 2004·Application pending·0 cites
- 1956US2024016839A1Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapiesIMMPACT BIO USA INC·Filed 2021·Application pending·0 cites
- 2050US11629184B2Calcitonin gene-related peptide (CGRP) antagonist antibodiesREMD BIOTHERAPEUTICS INC·Filed 2019·Granted Apr 18, 2023·0 cites·16 claims
- 2150US11319376B2Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancerREMD BIOTHERAPEUTICS INC·Filed 2017·Granted May 3, 2022·0 cites·13 claims
- 2250US2005147611A1Combination therapy for conditions leading to bone lossAMGEN INC·Filed 2005·Application pending·0 cites
- 2349US11078288B2Methods and compositions for treating tumor diseasesAMGEN INC·Filed 2018·Granted Aug 3, 2021·0 cites·20 claims
- 2448US11332531B2Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)REMD BIOTHERAPEUTICS INC·Filed 2017·Granted May 17, 2022·0 cites·19 claims
- 2546US11248049B2Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)REMD BIOTHERAPEUTICS INC·Filed 2017·Granted Feb 15, 2022·0 cites·19 claims
- 2646US11242398B2Anti-OX40 antibodies and methods of activating OX40REMD BIOTHERAPEUTICS INC·Filed 2018·Granted Feb 8, 2022·0 cites·16 claims
- 2745US2010166747A1Methods and compositions for treating tumor diseasesBELTRAN PEDRO J·Filed 2008·Application pending·0 cites
- 2841US2005123512A1Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereofAMGEN INC A CORP OF THE STATE·Filed 2003·Application pending·0 cites
- 2940US2021079087A1Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)REMD BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3039US2002064823A1CD20/IgE-receptor like molecules and uses thereofFiled 2001·Application pending·0 cites
- 3132US2003207827A1OsteoprotegerinFiled 1999·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →